MedPath

Pilot evaluation of modified cognitive behavioral therapy for elderly patients with schizophrenia

Not Applicable
Conditions
DSM-IV 295.30 Schizophrenia, paranoid typeDSM-IV 295.10 Schizophrenia disorganized typeDSM-IV 295.90 Schizophrenia undifferentiated typeDSM-IV 295.60 Schizophrenia residual typeDSM-IV 295.40 Schizophreniform disorderDSM-IV 295.70 Schizoaffective disorderDSM-IV 197.1 Delusional disorder
F20
F25
F22
Schizophrenia
Schizoaffective disorders
Persistent delusional disorders
Registration Number
DRKS00003623
Lead Sponsor
Klinik für Psychiatrie und Psychotherapie, LVR-Klinikum Essen, Klinik der Universität Duisburg-Essen
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

DSM-IV Schizophrenia diagnosis: 295.30, 295.10, 295.9, 295.60, 295.40, 295.70, 297.1;
illness duration > 10 years;
MWT-B IQ > 75;
physical ability for self-initiated activities;
psychic stability for outpatient treatment;
fluency of German language;
contact person with >/= 10 h contacts / week;
travel time to study site < 1 hour

Exclusion Criteria

Dementia; unsuccessfully treated diabetes; dependency or substance abuse of psychoactive substances which needs to be treated; Stroke or acute or chronic heart disease within 3 month before inclusion into the study; chronic nervous system related inflammation; malign tumor, major depression (severe)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in one of three:<br>1. Symptoms: Positive and negative syndrom scale (PANSS) total score: Structured Interview on symptoms in schizophrenia; <br>2. Depression symptoms: Calgary Depression Rating Scale for Schizophrenia German Version (CDSS-G), Questionaire to be conducted by study participants<br>3. Functional abilities: UPSA-Brief - University of California, San Diego, Performance-Based Skills Assessment, Rating of study participants behaviour in simple tasks related to standardized situations. <br>Primary endpoints are assessed following randomization (before treatment start), following 4.5 month in the study, following 9 month in the study (treatment end) and following 15 month in the study (6 month follow-up). Outcome no. 3 is not assessed at 4.5 month.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath